Novartis AG ADR (NVS)vsRxsight Inc (RXST)
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
RXST
Rxsight Inc
$5.00
-1.96%
HEALTHCARE · Cap: $200.39M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 44283% more annual revenue ($56.58B vs $127.48M). NVS leads profitability with a 23.9% profit margin vs -36.6%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
RXST
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+72.3%
Fair Value
$29.00
Current Price
$5.00
$24.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RXST
The strongest argument for RXST centers on Price/Book, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : RXST
The primary concerns for RXST are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while RXST is a turnaround play — different risk/reward profiles.
RXST carries more volatility with a beta of 1.13 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 34/100), backed by strong 23.9% margins. RXST offers better value entry with a 72.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rxsight Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rxsight Inc. is a pioneering healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye surgery. Utilizing proprietary software and precision-guided laser systems, Rxsight aims to significantly improve patient outcomes and quality of life for those seeking vision correction. The firm maintains a robust intellectual property portfolio and cultivates strategic partnerships, positioning itself strongly within the expanding ophthalmic market. With a commitment to innovation and operational excellence, Rxsight is poised for considerable growth and a transformative impact within the eye care sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?